Announced Fri, 29 May · 19:19 IST

We attach herewith the following: a. Declaration of unmodified opinion b. Audited Financial Results for he quarter/year ended March 31, 2026, Declaration of unmodified opinion, Auditors ....

Revenue Growth 20pctPat NegativeEbitda Margin ExpansionDebt Equity ThresholdResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-9.7%1-day move
₹88.01
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-9.7-14.2-18.4-14.8-14.8-16.5-18.1
Up moveDown movePending
AI summary

Raaj Medisafe India reported FY2026 revenue of ₹8,001.46 Lakhs, up 28.2% from ₹6,242.04 Lakhs in FY2025, driven by strong growth in the Hygiene Division (revenue more than doubled to ₹2,654.57 Lakhs). However, profit after tax fell sharply to ₹180.97 Lakhs from ₹613.12 Lakhs in the prior year — a 70.5% decline — due to a large deferred tax charge of ₹345.73 Lakhs arising in Q4, which pushed the quarter into a net loss of ₹322.63 Lakhs despite ₹128.62 Lakhs PBT. PBT grew 20.3% to ₹632.23 Lakhs (vs ₹525.48 Lakhs). The company raised ₹1,801.25 Lakhs via a preferential share issue (32.75 lakh shares at ₹55/share) and is undertaking a strategic capacity expansion expected to complete in FY2027. Total assets grew to ₹12,134.87 Lakhs (vs ₹6,921.65 Lakhs), largely due to a near doubling of borrowings. Cash and cash equivalents improved significantly to ₹1,301.01 Lakhs. Auditors issued an unmodified opinion.

Likely market impact

Strong revenue growth is overshadowed by a sharp PAT decline, largely due to a deferred tax expense in Q4. The large one-off tax charge masks underlying operating strength; however, the heavy reliance on borrowings and capex expansion warrants monitoring.